LCL521-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemELCL521Cat.No.:HY-103593CASNo.:1226851-11-1分?式:C??H??N?O?分?量:592.77作?靶點(diǎn):Phospholipase作?通路:MetabolicEnzyme/Protease儲(chǔ)存?式:Pureform-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:165mg/mL(278.35mM;Needultrasonic)Ethanol:100mg/mL(168.70mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.6870mL8.4350mL16.8699mL5mM0.3374mL1.6870mL3.3740mL10mM0.1687mL0.8435mL1.6870mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.75mg/mL(4.64mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請(qǐng)依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.75mg/mL(4.64mM);Clearsolution3.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.75mg/mL(4.64mM);ClearsolutionBIOLOGICALACTIVITY?物活性LCL521?種酸性神經(jīng)酰胺酶(ACDase)抑制劑。LCL521還抑制溶酶體酸性鞘磷脂酶(ASMase)。IC50&TargetACDase,ASMase[1]體外研究LCL521(1μM)actsasapotentinhibitorofcellularACDaseactivity,whereas10μMLCL521hasanadditional,decreasedaffectontheα-formofthisenzyme.LCL521(10μM)causesatime-dependent(1hoursand5hours)decreaseoftheα-ACDaseforminMCF7cells[1].REFERENCES[1].BaiA,etal.Targeting(cellular)lysosomalacidceramidasebyB13:design,synthesisandevaluationofnovelDMG-B13esterprodrugs.BioorgMedChem.2014Dec15;22(24):6933-44.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-379